Contribution of lateral substituents in symmetrical and non-symmetrical heptane-bisammonio compounds to the allosteric stabilization of N-methylscopolamine binding to muscarinic M2 receptors.
Allosteric modulators are able to enhance or decrease the equilibrium binding of orthosteric agonists or antagonists. The treatment of Alzheimer's disease and the organophosphorus poisoning can take advantage of the enhancement of the ligand binding. Prerequisite is the formation of ternary complexes consisting of the receptor protein, the orthosteric ligand, e. g. N-methylscopolamine (NMS), and the alloster optimized for the corresponding orthoster. In this study, heptane-bisammonio compounds were optimized with regard to the orthosteric antagonist NMS. Comparing pairs of compounds characterized by phthalimides, cyclohexanedicarbonic acid imide and succinimides at both ends or a phthalimide at one end and either of the three imides at the other end stressed the importance of an aromatic moiety at both ends of the heptane-bisammonio chain.
D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D066298:In Vitro Techniques; D007202:Indicators and Reagents; D009682:Magnetic Resonance Spectroscopy; D008968:Molecular Conformation; D018721:Muscarinic Agonists / Q000138:chemical synthesis* / Q000494:pharmacology*; D018727:Muscarinic Antagonists / Q000138:chemical synthesis* / Q000494:pharmacology*; D019832:N-Methylscopolamine / Q000378:metabolism*; D043585:Receptor, Muscarinic M2; D011976:Receptors, Muscarinic / Q000187:drug effects*; D013329:Structure-Activity Relationship; D013552:Swine
D007202:Indicators and Reagents; D018721:Muscarinic Agonists; D018727:Muscarinic Antagonists; D043585:Receptor, Muscarinic M2; D011976:Receptors, Muscarinic; D019832:N-Methylscopolamine